Advanced Genomics Tools Will Shape Future Precision Medicine

Key Takeaways

• Expansion of product offerings and strategic acquisitions are enhancing innovation, reducing operational costs, and solidifying leadership in advanced genomics tools.
  
• Growth in global partnerships and improved international presence are increasing market opportunities and supporting resilient, long-term revenue streams.
  
• Macroeconomic pressures, shrinking pricing power, product shifts, and ongoing losses are undermining revenue growth, margin stability, and the path to profitability.

Catalysts

A life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the Americas, Europe, the Middle East, Africa, China, and the Asia Pacific.

• Adoption of new lower-cost consumables (like GEM-X Flex and Universal On Chip Multiplex) is increasing reaction volumes and enabling scale, positioning 10x Genomics to capture growing demand in single-cell and multiomic analysis driven by precision medicine, likely supporting long-term revenue and recurring, high-margin consumables sales.
  
• Recent and upcoming product launches-including Flex v2 (targeting higher throughput, lower costs, and AI integration), Visium HD extensions, and Xenium RNA plus protein-are expanding the range of applications and reinforcing 10x's leadership in advanced genomics tools, expected to drive both top-line growth and sustain premium pricing over time.
  
• The acquisition of Scale Biosciences broadens 10x Genomics' technical capabilities in single-cell analysis, allowing integration of foundational innovations like combinatorial indexing and quantum barcoding, which may accelerate innovation, reduce costs, and open up new high-value markets, positively impacting future revenue growth and margins.
  
• Global investment in genomics, including collaborations like the TISHUMAP initiative and large-scale AI-driven studies using 10x platforms, is increasing the customer base and creating new high-throughput, high-complexity data requirements-which 10x is well positioned to supply, driving expanded total addressable market and future revenue upside.
  
• Strengthening international distribution, particularly improved execution in China and Europe, together with strategic responses to tariff and CapEx headwinds, helps 10x diversify regional risks and access untapped markets, enhancing revenue growth resilience despite the currently challenging US academic funding environment.

10x Genomics Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

• Analysts are assuming 10x Genomics's revenue will grow by 5.7% annually over the next 3 years.
• Analysts are not forecasting that 10x Genomics will become profitable in next 3 years. To represent the Analyst Price Target as a Future PE Valuation we will estimate 10x Genomics's profit margin will increase from -3.5% to the average US Life Sciences industry of 15.9% in 3 years.
• If 10x Genomics's profit margin were to converge on the industry average, you could expect earnings to reach $120.2 million (and earnings per share of $0.89) by about August 2029, up from -$22.7 million today.
• In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 58.3x on those 2029 earnings, up from -265.9x today. This future PE is greater than the current PE for the US Life Sciences industry at 42.7x.
• Analysts expect the number of shares outstanding to grow by 1.98% per year for the next 3 years.
• To value all of this in today's terms, we will use a discount rate of 7.8%, as per the Simply Wall St company report.

Risks

• Ongoing macroeconomic and funding uncertainty, especially in the US and Europe, is dampening academic and government research budgets, leading to conservative spending, extended project timelines, delays in equipment purchases, and heightened price sensitivity-directly pressuring future revenue growth and earning stability.
  
• Lower average selling prices and continued discounting of instruments (notably Chromium and spatial platforms) to address customers' CapEx constraints indicate shrinking pricing power and may compress gross margins over time, especially as capital spending headwinds persist.
  
• Product transitions to lower-cost solutions (e.g. GEM-X Flex, Flex v2, and Scale Biosciences' combinatorial indexing), while driving higher reaction volumes, are creating a near-term headwind to consumables revenue growth, as price declines are not yet fully offset by increased volume, risking overall revenue and operating leverage.
  
• Temporary boosts in key geographies (such as APAC/China) from one-off events like tariff-related pull forwards may not be sustainable, while geopolitical risks and possible export restrictions could impact international expansion potential and geographically diversify revenue streams.
  
• Persistent operating losses (excluding one-off gains from litigation settlements) and the need for ongoing cost discipline in R&D and SG&A suggest that, despite cash reserves, the business remains vulnerable to weaker top-line performance and delayed return to profitability-making net earnings recovery uncertain in a prolonged challenging environment.

Valuation

How have all the factors above been brought together to estimate a fair value?

• The analysts have a consensus price target of $41.54 for 10x Genomics based on their expectations of its future earnings growth, profit margins and other risk factors.
• However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $50.0, and the most bearish reporting a price target of just $25.0.
• In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be $754.6 million, earnings will come to $120.2 million, and it would be trading on a PE ratio of 58.3x, assuming you use a discount rate of 7.8%.
• Given the current share price of $47.46, the analyst price target of $41.54 is 14.3% lower. Despite analysts expecting the underlying business to improve, they seem to believe the market's expectations are too high.
• We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.